|
|
|
|
|
|
|
|
|
|
|
|
|
02.03.26 - 13:33
|
Altimmune to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:...
|
|
|
|
|
|
|
29.01.26 - 23:57
|
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire EN)
|
|
|
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The gross proceeds to the Company were approximately $75 million, before deducting placement agent fees and other offering expenses. All of the shares and pre-funded warrants in the offering are being offered by Altimmune. The pre-funded warrants have an exercise price of $0.001 per share, are exercisable immediately upon issuance and will not expire until fully exercised....
|
|
|
|
|
|
|
|
|
28.01.26 - 03:27
|
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire EN)
|
|
|
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The offering is expected to result in gross proceeds of approximately $75 million, before deducting placement agent fees and other offering expenses. All of the shares and pre-funded warrants in the offering are being offered by Altimmune. The offering is expected to close on or about January 29, 2026, subject to the satisfaction of customary closing conditions....
|
|
|
23.01.26 - 20:12
|
Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly (24/7 Wall St.)
|
|
|
Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic diseases and became one of the highest-rated stocks in social sentiment tracking after the FDA granted Breakthrough Therapy Designation for its lead drug pemvidutide on January 16. ... Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly
The post Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
